Successful treatment with ustekinumab of psoriasis vulgaris in a patient undergoing hemodialysis
Successful treatment with ustekinumab of psoriasis vulgaris in a patient undergoing hemodialysis
复制标题
DOI：
10.1111/1346-8138.12989
复制
发表时间：
2016-01-01
影响因子：
3.1
通讯作者：
Tsuruta, Daisuke
中科院分区：
文献类型：
--
作者：
Nimmannitya, Kulsupa;Tateishi, Chiharu;Tsuruta, Daisuke
银屑病是一种常见的慢性炎症性皮肤病，但银屑病患者合并肾功能损害进行透析并不常见。此外，已发表的工作包含的信息与终末期肾病患者的生物药物的治疗很少。我们描述一位57岁男性，患有难治性斑块型银屑病及因多囊肾病而导致的终末期肾病，并接受血液透析治疗。他曾尝试外用药物和紫外线治疗多年，然后接受乌司奴单抗（一种白细胞介素-12和白细胞介素-23阻滞剂）治疗，临床反应良好，沿着肾功能稳定。经过几年的治疗，没有观察到任何副作用。我们对该患者的经验扩大了乌司奴单抗的范围，使其包括接受血液透析的肾衰竭银屑病患者。
Psoriasis is a common chronic inflammatory skin disease but psoriasis patients with renal impairment undergoing dialysis are not frequently seen. Furthermore, the published work contains little information on the treatment with biologic drugs of patients with end-stage renal disease. We describe a 57-year-old man with refractory plaque-type psoriasis and end-stage renal disease due to polycystic kidney disease undergoing hemodialysis. He had tried topical medications and ultraviolet therapy for many years and was then treated with ustekinumab (an interleukin-12 and interleukin-23 blocker), which resulted in good clinical response along with stable renal function. After a few years of therapy, no side-effects have been observed. Our experience with this patient expands the spectrum of ustekinumab to include psoriasis patients with renal failure undergoing hemodialysis.